(Q38255364)

1 September 2017

1 reference

title

Vancomycin nephrotoxicity: a review (English)

1 reference

1 September 2017

1 reference

Kari A Mergenhagen

1

1 reference

1 September 2017

Angela R Borton

series ordinal

2

1 reference

1 September 2017

publication date

28 September 2014

1 reference

Journal of Pharmacy Practice

1 September 2017

published in

1 reference

1 September 2017

volume

27

1 reference

1 September 2017

issue

6

1 reference

1 September 2017

page(s)

545-553

1 reference

1 September 2017

cites work

Vancomycin: a history

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Vancomycin: a 50-year reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Tubulointerstitial nephritis due to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycosides in septic critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Nephrotoxicity of vancomycin, alone and with an aminoglycoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190014546114

21 January 2018

Identifiers

DOI

10.1177/0897190014546114

1 reference

1 September 2017

1 reference